Eli Lilly expands Zepbound access for long-term growth

What happened: Eli Lilly (LLY) expanded access to its obesity drug, Zepbound, following FDA approval in June 2023. The company's pipeline includes promising drugs like Foundayo and Retatrutide, which could solidify its dominance in the anti-obesity market. Eli Lilly secured a $2.75 billion deal with Insilico to bring AI-developed drugs to market. Jim Cramer and analysts have praised Eli Lilly's growth prospects, with price targets suggesting 20-30% upside.

Market impact: The obesity drug market is heating up, with Eli Lilly and Novo Nordisk vying for dominance. Zepbound's expanded access and Eli Lilly's pipeline could drive growth and boost the company's valuation. The deal with Insilico signals Eli Lilly's commitment to AI-driven drug development, potentially reshaping the pharmaceutical landscape.

What to watch next: Eli Lilly's Q2 earnings, scheduled for August 3, will provide insights into Zepbound's commercial performance and pipeline progress. The FDA's decision on Foundayo, expected in Q4 2023, will be a critical catalyst. Additionally, investors should monitor regulatory developments around Retatrutide, currently in phase 3 trials.